• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600511.SS
Share

China National Medicines Corporation Ltd. Stocks

CN¥ 26.63Last Updated 09.10.2026

Issuer Rating

7/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 2.94B

CN¥ 26.63
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

China National Medicines Corporation Ltd., in conjunction with its various operating entities, is a prominent player in the distribution of pharmaceutical goods across China. The enterprise's scope extends to the production and commercialization of innovative as well as pre-existing drug formulations. Additionally, it markets both traditional Chinese patent remedies and modern Western medications, alongside a range of medical apparatus. Complementing these activities, the firm delivers warehousing solutions and acts as an agent for import and export transactions. Its diverse clientele encompasses hospitals, retail pharmacies, and other healthcare organizations. Established in 1999, the company maintains its principal office in Beijing, China.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 600511.SS is 35.2 and suggests 31.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

10.10.2026 04:25

Apple has cut orders for parts for the new iPhones, according to media reports. Was demand lower than expected?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026